PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34284042-6	2021	In contrast, alpha5-NAM treatment from DIV19-21, when hyperpolarizing GABAAR signaling predominates, enhances surface synaptic GluN2A while decreasing GluN2B.	alpha5-nam	13-23	gamma-aminobutyric acid (GABA) A receptor, subunit gamma 2	Mus musculus	70-76	
34284042-6	2021	In contrast, alpha5-NAM treatment from DIV19-21, when hyperpolarizing GABAAR signaling predominates, enhances surface synaptic GluN2A while decreasing GluN2B.	alpha5-nam	13-23	glutamate receptor, ionotropic, NMDA2A (epsilon 1)	Mus musculus	127-133	
34284042-6	2021	In contrast, alpha5-NAM treatment from DIV19-21, when hyperpolarizing GABAAR signaling predominates, enhances surface synaptic GluN2A while decreasing GluN2B.	alpha5-nam	13-23	glutamate receptor, ionotropic, NMDA2B (epsilon 2)	Mus musculus	151-157	
34284042-9	2021	Furthermore, alpha5-NAM inhibition of the GABAAR tonic current in mature neurons is maintained after 2-day alpha5-NAM treatment, suggesting reduced tolerance liability, in contrast to other clinically relevant GABAAR-targeting drugs such as benzodiazepines.	alpha5-nam	13-23	gamma-aminobutyric acid (GABA) A receptor, subunit gamma 2	Mus musculus	42-48	
34284042-9	2021	Furthermore, alpha5-NAM inhibition of the GABAAR tonic current in mature neurons is maintained after 2-day alpha5-NAM treatment, suggesting reduced tolerance liability, in contrast to other clinically relevant GABAAR-targeting drugs such as benzodiazepines.	alpha5-nam	107-117	gamma-aminobutyric acid (GABA) A receptor, subunit gamma 2	Mus musculus	42-48	
34284042-9	2021	Furthermore, alpha5-NAM inhibition of the GABAAR tonic current in mature neurons is maintained after 2-day alpha5-NAM treatment, suggesting reduced tolerance liability, in contrast to other clinically relevant GABAAR-targeting drugs such as benzodiazepines.	Benzodiazepines	241-256	gamma-aminobutyric acid (GABA) A receptor, subunit gamma 2	Mus musculus	210-216